Eli Lilly to Acquire Centessa in $7.8 B Deal Targeting Narcolepsy Therapies

Eli Lilly disclosed on March 31, 2026 that it will acquire Centessa for a maximum consideration of $7.8 billion, a strategic step to strengthen its pipeline in the sleep‑disorder space. The acquisition is expected to bring several experimental narcolepsy candidates into Lilly’s research and development framework. The deal positions Lilly at the forefront of a growing segment of neurology that seeks to address narcolepsy, a condition characterized by excessive daytime sleepiness and sudden loss of muscle tone. By integrating Centessa’s early‑stage programs, Lilly aims to accelerate the path from laboratory to market for novel therapeutics that could fill a notable gap in current treatment options. Centessa is among a handful of companies pursuing a new class of drugs designed specifically for narcolepsy. While the firm’s portfolio remains in the experimental phase, the acquisition provides Lilly with access to promising assets and scientific expertise that complement its existing neurology initiatives. Industry observers view the transaction as a reflection of broader market dynamics, where major pharmaceutical players are increasingly allocating capital toward sleep‑disorder research. The purchase may reshape competitive dynamics, influencing both current and future entrants in the narcolepsy space, and could impact investors tracking the performance of both companies.